Precision medicine
Also known as: personalized medicine, individualized medicine
Precision medicine is an approach to healthcare that tailors prevention, diagnosis, and treatment to individual differences in genes, biology, environment, and lifestyle.
The best-known examples are in cancer, where drugs target specific mutations in a tumour. While the idea promises 'the right treatment for the right patient at the right time,' precision medicine has so far transformed some diseases dramatically and others barely at all.
Precision medicine, explained at three levels
At home
Think of buying glasses. A store could sell everyone the same lenses, but an eye exam measures your vision so your lenses fit you. Precision medicine applies that idea to treatment. Doctors test for differences in your genes, your tumour, or other biology, then choose the prevention or treatment most likely to work for you, instead of the one that works best on average.
At work
Precision medicine tailors diagnosis and treatment to individual biology, using biomarker tests, genomic sequencing, and data on environment and lifestyle. Its clearest results are in cancer, where tests match tumours to targeted drugs. For health systems, it can raise success rates and avoid ineffective treatments, but it requires testing infrastructure, data systems, and budgets for expensive drugs.
At home
Precision medicine often works through a biomarker, a measurable sign such as a gene mutation or protein level. In lung cancer, for example, a tumour sample is tested for changes in genes such as EGFR or ALK. If the tumour has an EGFR mutation, a targeted pill can block the faulty signal driving its growth, often working better and with fewer side effects than standard chemotherapy. If no matching change is found, standard treatment remains the choice.
At work
The core unit is a biomarker paired with a decision. Companion diagnostics are tests approved alongside a specific drug, such as HER2 testing for trastuzumab. Labs now run NGS panels that check dozens of genes at once. Results feed tumour boards and EHR systems that link variants to therapies and trials. Pharmacogenomics adds drug-dosing guidance. Beyond cancer, the approach covers rare diseases, cystic fibrosis drugs matched to specific mutations, and parts of cardiology.
At home
Targeted drugs work because they hit one specific driver, which also limits them. Tumours often evolve around the blocked pathway, so resistance develops within months or years. Each drug helps only patients with the matching change, so prices per patient are high. While the science is impressive, in my opinion precision medicine raises fairness questions: who gets tested, and who can afford the treatments the tests recommend?
At work
Precision medicine is a chain: test, interpret, decide, treat, and pay, and each link can fail. Test reimbursement and turnaround times delay treatment. Variant interpretation needs molecular tumour boards. Results must reach the EHR in structured form. Basket trials, which group patients by mutation across tumour types, and umbrella trials, which test several drugs within one cancer, changed how evidence is built. Health technology assessment struggles with small populations and single-arm evidence.
Real-world examples
At home
Aisha's uncle in Vancouver was diagnosed with lung cancer. Tumour testing found a mutation with a matching targeted therapy, and he took a daily pill instead of intensive chemotherapy, with far fewer side effects.
At work
Fatima is an oncology program manager at a Canadian cancer centre. Her team cut genomic test turnaround from four weeks to under two, so patients with advanced cancers could start targeted therapy sooner.
How it compares
| feature | Precision medicine | Standard care |
|---|---|---|
| Approach | Tailored to individual characteristics | Based on average patient results |
| Testing | Biomarkers and genetics | Standard diagnostic tests |
| Cost | Often higher per patient | Usually lower |
| Best example | Targeted cancer therapy | Guideline-based treatment for common conditions |
Precision medicine treats the patient's specific biology, not the average patient.
For analysts
Precision medicine depends on a chain: test, interpret, treat, and pay. I'd map that chain end to end in any program, since a broken link, like slow testing or no drug coverage, wastes the rest of the investment.
History & origin
Doctors have always tailored care, but molecular biology made it far more precise. Herceptin, approved in the US in 1998 for breast cancers with high HER2 levels, was an early targeted therapy paired with a test. Gleevec (imatinib), approved in 2001, turned chronic myeloid leukemia from a deadly cancer into a manageable condition for many patients. The Human Genome Project in 2003 and falling sequencing costs expanded the field. In 2015, US President Barack Obama announced the Precision Medicine Initiative, leading to the All of Us research program. In Canada, programs such as BC Cancer's Personalized OncoGenomics have sequenced tumours to guide treatment. In my view, precision medicine's biggest successes came from pairing a specific test with a specific drug, not from collecting data in the hope that insight would follow.